A 28-year-old man with a history of recurrent episodes of muscle paralysis associated with low serum potassium is suspected to have hypokalemic periodic paralysis. Which investigation would best confirm the diagnosis by directly demonstrating the underlying defect in ion channel function at the neuromuscular junction?

Explanation

## Diagnosis of Hypokalemic Periodic Paralysis ### Pathophysiology Hypokalemic periodic paralysis is a channelopathy — a disorder of ion channel function at the neuromuscular junction and skeletal muscle membrane. The defect impairs normal potassium regulation during muscle activity, leading to sudden shifts of K^+^ into muscle cells and causing paralysis. ### Why Genetic Testing is Correct **Key Point:** Genetic testing for mutations in **CACNA1S** (L-type calcium channel α1S subunit) or **SCN4A** (skeletal muscle sodium channel) genes is the gold standard for confirming hypokalemic periodic paralysis. **High-Yield:** These mutations directly cause the channelopathy: - **CACNA1S mutations** account for ~60–70% of hypokalemic periodic paralysis cases - **SCN4A mutations** account for ~20% of cases - Mutations impair ion channel gating and calcium/sodium handling, disrupting the electrical-mechanical coupling at the neuromuscular junction **Clinical Pearl:** Genetic testing: - Provides definitive diagnosis - Allows family screening and genetic counseling - Guides management (avoid triggers like rest after exercise, high-carbohydrate meals) - Is the only investigation that identifies the **underlying molecular defect** ### Diagnostic Algorithm for Hypokalemic Periodic Paralysis ```mermaid flowchart TD A[Clinical suspicion:<br/>Recurrent paralysis + hypokalemia]:::outcome --> B{Serum K+ during attack?}:::decision B -->|Low| C[Hypokalemic periodic paralysis likely]:::outcome C --> D{Genetic testing<br/>CACNA1S or SCN4A}:::decision D -->|Mutation found| E[Diagnosis confirmed]:::action D -->|No mutation| F[Consider other channelopathies<br/>or secondary causes]:::action B -->|Normal| G[Exclude other causes:<br/>thyrotoxicosis, RTA]:::action ``` ### Why Genetic Testing Over Other Investigations | Investigation | What It Shows | Diagnostic Value | |---|---|---| | **Genetic testing** | Direct ion channel mutation | **Definitive diagnosis; identifies underlying defect** | | **Serum K+ during attack** | Low potassium | Supports diagnosis but non-specific; also seen in thyrotoxic periodic paralysis, RTA | | **Ischemic forearm exercise test** | Lactate response; muscle metabolism | Useful for myopathy screening; does not identify ion channel defect | | **Muscle biopsy** | Histology; calcium deposits (vacuoles) | Shows secondary changes; not diagnostic for channelopathy | **Mnemonic:** **CACNA1S = Calcium channel** (most common); **SCN4A = Sodium channel** — both are **ion channel genes** that cause hypokalemic periodic paralysis. ### Why Genetic Testing is Superior - **Specificity:** Identifies the exact molecular defect causing the channelopathy - **Definitive:** Confirms diagnosis even when serum K^+^ is normal between attacks - **Prognostic:** Guides long-term management and family counseling - **Non-invasive:** No need for muscle biopsy or exercise testing ### Limitations of Other Tests - Serum K^+^ during attack: Non-specific; can be low in other conditions (thyrotoxicosis, RTA, hypokalemic myopathy) - Ischemic forearm exercise test: Assesses muscle metabolism, not ion channel function - Muscle biopsy: Shows secondary vacuolar changes; does not identify the genetic defect